These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18342708)

  • 21. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Defuentes G; Bladé JS; Berets O
    N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
    [No Abstract]   [Full Text] [Related]  

  • 25. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
    J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
    [No Abstract]   [Full Text] [Related]  

  • 26. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeted drug therapies and cancer.
    Yim KL; Cunningham D
    Recent Results Cancer Res; 2011; 185():159-71. PubMed ID: 21822826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
    Force T; Krause DS; Van Etten RA
    Nat Rev Cancer; 2007 May; 7(5):332-44. PubMed ID: 17457301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 31. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adverse drug reactions induced by molecular target therapy].
    Kano Y
    Arerugi; 2007 Dec; 56(12):1485-91. PubMed ID: 18195551
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Renal tolerance of targeted therapies].
    Thariat J; Janus N; Barrière J; Launay-Vacher V
    Bull Cancer; 2012 Mar; 99(3):317-22. PubMed ID: 22146132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
    Rodarte CM; Abdallah OA; Barbosa NF; Koch Lde O; Resende UM
    An Bras Dermatol; 2009; 84(6):667-70. PubMed ID: 20191181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
    Ara M; Pastushenko E
    Actas Dermosifiliogr; 2014 Dec; 105(10):900-12. PubMed ID: 24766821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.